Utilization of monoclonal antibody-targeted nanomaterials in the treatment of cancer

mAbs

Volumn 3, Issue 5, 2011, Pages 467-478

  Julien, Daniel C ^a,b   Behnke, Steven ^a   Wang, Guankui ^a   Murdoch, Gordon K ^a   Hill, Rodney A ^a  

^a UNIVERSITY OF IDAHO   (United States)

^b University of Washington School of Medicine   (United States)

Author keywords

Cancer; Immunotherapy; Nanomaterial; Nanomedicine

Indexed keywords

ALEMTUZUMAB; ANTIBODY CONJUGATE; BEVACIZUMAB; CARBON; CATUMAXOMAB; CD20 ANTIBODY; CETUXIMAB; COPOLYMER; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPITOPE; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LIPOSOME; METAL; MONOCLONAL ANTIBODY; NANOMATERIAL; OFATUMUMAB; PANITUMUMAB; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; POLOXAMER; POLYOXYETHYLENE; RITUXIMAB; SILICON DIOXIDE; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; YERVOY;

ANGIOGENESIS; ANTIBODY SPECIFICITY; B CELL LYMPHOMA; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG APPROVAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; ENDOSOME; HUMAN; KIDNEY CANCER; LUNG CANCER; LYSOSOME; MELANOMA; MICELLE; MOLECULAR INTERACTION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PARTICLE SIZE; REVIEW; TUMOR VASCULARIZATION;

ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOTHERAPY; NANOCONJUGATES; NANOMEDICINE; NANOSTRUCTURES; NEOPLASMS;

EID: 80052577148     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.3.5.16089     Document Type: Review

References (112)

1. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-7.
2. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies. Hum Antibodies 2009; 18:81-100.
3. Natarajan A, Xiong CY, Gruettner C, DeNardo GL, DeNardo SJ. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. Cancer Biother Radiopharm 2008; 23:82-91.
4. Sachdeva MS. Drug targeting systems for cancer chemotherapy. Expert Opin Investig Drugs 1998; 7:1849-64.
5. Sinha R, Kim GJ, Nie S, Shin DM. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol Cancer Ther 2006; 5:1909-17.
6. Stewart BaK P. World Cancer Report. World Health Organization 2003.
7. Tsuruo T, Naito M, Tomida A, Fujita N, Mashima T, Sakamoto H, et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94:15-21.
8. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat Rev 2008; 34:592-602.
9. Liu X, Wang X, Wei D, Cai M, Li G. [Internalization of antibody-targeted immunonanoparticles into human hepatoma cells and its reversal effect on MDR]. Sichuan Da Xue Xue Bao Yi Xue Ban 2003; 34:431-4.
10. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin 2008; 58:97-110.
11. Pietersz GA, Kanellos J, Smyth MJ, Zalcberg J, McKenzie IF. The use of monoclonal antibody conjugates for the diagnosis and treatment of cancer. Immunol Cell Biol 1987; 65:111-25.
12. Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res 2006; 23:1417-50.
13. Walker B Jr, Mouton CP. Nanotechnology and nanomedicine: a primer. J Natl Med Assoc 2006; 98:1985-8.
14. National Nanotechnology Initiative 2010; www.nano.gov/
15. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 2007; 150:552-8.
16. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J 2005; 19:311-30.
17. Poole CP. Introduction to Nanotechnology. Hoboken, New Jersey: John Wiley and Sons 2003.
18. Hassan M. Nanotechnology. Science 2004; 304:1732-4.
19. Webster TJ. Nanomedicine: what's in a definition? International Journal of Nanomedicine 2006; 1:115-6.
20. Oh P, Li Y, Yu J, Durr E, Krasinska KM, Carver LA, et al. Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy. Nature 2004; 429:629-35.
21. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine 2008; 3:133-49.
22. Jain KK. Role of nanobiotechnology in developing personalized medicine for cancer. Technol Cancer Res Treat 2005; 4:645-50.
23. Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J 2007; 9:128-47.
24. de Silva MN. Nanotechnology and nanomedicine: a new horizon for medical diagnostics and treatment. Arch Soc Esp Oftalmol 2007; 82:331-4.
25. Polakis P. Arming antibodies for cancer therapy. Curr Opin Pharmacol 2005; 5:382-7.
26. Doronina SO, Toki BE, Torgov MY, Mendelsohn BA, Cerveny CG, Chace DF, et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21:778-84.
27. Kaneko T, Willner D, Monkovic I, Knipe JO, Braslawsky GR, Greenfield RS, et al. New hydrazone derivatives of adriamycin and their immunoconjugates -a correlation between acid stability and cytotoxicity. Bioconjug Chem 1991; 2:133-41.
28. Hamann PR, Hinman LM, Beyer CF, Lindh D, Upeslacis J, Flowers DA, et al. An anti-CD33 antibodycalicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem 2002; 13:40-6.
29. Sanderson RJ, Hering MA, James SF, Sun MM, Doronina SO, Siadak AW, et al. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate. Clin Cancer Res 2005; 11:843-52.
30. Ulbrich K, Etrych T, Chytil P, Jelinkova M, Rihova B. Antibody-targeted polymer-doxorubicin conjugates with pH-controlled activation. J Drug Target 2004; 12:477-89.
31. Xia CF, Boado RJ, Pardridge WM. Antibody-mediated targeting of siRNA via the human insulin receptor using avidin-biotin technology. Mol Pharm 2009; 6:747-51.
32. Xia CF, Zhang Y, Boado RJ, Pardridge WM. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007; 24:2309-16.
33. Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res 2010; 2:14.
34. Greenwald RB. PEG drugs: an overview. J Control Release 2001; 74:159-71.
35. John R, Rezaeipoor R, Adie SG, Chaney EJ, Oldenburg AL, Marjanovic M, et al. In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc Natl Acad Sci USA 2010; 107:8085-90.
36. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4:145-60.
37. Hofheinz RD, Gnad-Vogt SU, Beyer U, Hochhaus A. Liposomal encapsulated anti-cancer drugs. Anticancer Drugs 2005; 16:691-707.
38. Zhong YQ, Wei J, Fu YR, Shao J, Liang YW, Lin YH, et al. [Toxicity of cationic liposome Lipofectamine 2000 in human pancreatic cancer Capan-2 cells]. Nan Fang Yi Ke Da Xue Xue Bao 2008; 28:1981-4.
39. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55:3752-6.
40. Munn LL. Aberrant vascular architecture in tumors and its importance in drug-based therapies. Drug Discov Today 2003; 8:396-403.
41. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, et al. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann Oncol 2004; 15:517-25.
42. Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab' fragments and single chain Fv. J Control Release 2008; 126:50-8.
43. Kirpotin D, Park JW, Hong K, Zalipsky S, Li WL, Carter P, et al. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 1997; 36:66-75.
44. Crosasso P, Brusa P, Dosio F, Arpicco S, Pacchioni D, Schuber F, et al. Antitumoral activity of liposomes and immunoliposomes containing 5-fluorouridine prodrugs. J Pharm Sci 1997; 86:832-9.
45. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93:14164-9.
46. Xu L, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome- mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999; 10:2941-52.
47. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 2007; 18:101-8.
48. Rawat M, Singh D, Saraf S. Nanocarriers: promising vehicle for bioactive drugs. Biol Pharm Bull 2006; 29:1790-8.
49. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17:1263-8.
50. Li C. Poly(L-glutamic acid) - anticancer drug conjugates. Adv Drug Deliv Rev 2002; 54:695-713.
51. Lammers T, Hennink WE, Storm G. Tumour-targeted nanomedicines: principles and practice. Br J Cancer 2008; 99:392-7.
52. Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14:1310-6.
53. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803.
54. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2:347-60.
55. Gradishar WJ. Albumin-bound nanoparticle paclitaxel. Clin Adv Hematol Oncol 2005; 3:348-9.
56. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005; 23:7785-93.
57. Anhorn MG, Wagner S, Kreuter J, Langer K, von Briesen H. Specific targeting of HER2 overexpressing breast cancer cells with doxorubicin-loaded trastuzumab-modified human serum albumin nanoparticles. Bioconjug Chem 2008; 19:2321-31.
58. Wang Y, Liu X, Chen L, Cheng D, Rusckowski M, Hnatowich DJ. Tumor delivery of antisense oligomer using trastuzumab within a streptavidin nanoparticle. Eur J Nucl Med Mol Imaging 2009.
59. Fujita M, Lee BS, Khazenzon NM, Penichet ML, Wawrowsky KA, Patil R, et al. Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release 2007; 122:356-63.
60. Huang KH, Liu JH, Wang LY, Zhu ZH, Chen QK, Min J, et al. [Study of the anti-tumor effect of antivascular endothelial growth factor McAb 5-fluorouracil loaded polylactic acid nanoparticles]. Zhonghua Wei Chang Wai Ke Za Zhi 2007; 10:482-5.
61. Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 2006; 17:139-45.
62. Kos J, Obermajer N, Doljak B, Kocbek P, Kristl J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int J Pharm 2009; 381:106-12.
63. Lin HY, Landersdorfer CB, London D, Meng R, Lim CU, Lin C, et al. Pharmacodynamic modeling of anti-cancer activity of tetraiodothyroacetic acid in a perfused cell culture system. PLoS Comput Biol 2011; 7:1001073.
64. Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer 1996; 74:1545-52.
65. Nakanishi T, Fukushima S, Okamoto K, Suzuki M, Matsumura Y, Yokoyama M, et al. Development of the polymer micelle carrier system for doxorubicin. J Control Release 2001; 74:295-302.
66. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65:271-84.
67. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41:189-207.
68. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv Drug Deliv Rev 2001; 46:169-85.
69. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 2001; 74:47-61.
70. Roby A, Erdogan S, Torchilin VP. Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm 2006; 62:235-40.
71. Liao C, Sun Q, Liang B, Shen J, Shuai X. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide. Eur J Radiol 2010.
72. Sharma P, Brown S, Walter G, Santra S, Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interface Sci 2006.
73. Shim SY, Woo JR, Nam EJ, Hong HJ, Mook-Jung Kim YH, et al. Stepwise silver-staining-based immunosorbent assay for amyloid-beta autoantibody detection. Nanomedicine (Lond) 2008; 3:485-93.
74. Roca M, Haes AJ. Probing cells with noble metal nanoparticle aggregates. Nanomedicine (Lond) 2008; 3:555-65.
75. Kawano T, Yamagata M, Takahashi H, Niidome Yamada S, Katayama Y, et al. Stabilizing of plasmid DNA in vivo by PEG-modified cationic gold nanoparticles and the gene expression assisted with electrical pulses. J Control Release 2006; 111:382-9.
76. Niidome T, Yamagata M, Okamoto Y, Akiyama Takahashi H, Kawano T, et al. PEG-modified gold nanorods with a stealth character for in vivo applications. J Control Release 2006; 114:343-7.
77. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small 2005; 1:325-7.
78. Shenoy D, Fu W, Li J, Crasto C, Jones G, DiMarzio C, et al. Surface functionalization of gold nanoparticles using hetero-bifunctional poly(ethylene glycol) spacer for intracellular tracking and delivery. Int Nanomedicine 2006; 1:51-7.
79. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomedicine 2008; 4:273-82.
80. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, et al. In vitro and in vivo targeting hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther 2008; 7:1730-9.
81. Curley SA, Cherukuri P, Briggs K, Patra CR, Upton M, Dolson E, et al. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles. Exp Ther Oncol 2008; 7:313-26.
82. Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, et al. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res 2008; 68:1970-8.
83. Bianco A, Kostarelos K, Prato M. Applications of carbon nanotubes in drug delivery. Curr Opin Chem Biol 2005; 9:674-9.
84. Ashcroft JM, Tsyboulski DA, Hartman KB, Zakharian TY, Marks JW, Weisman RB, et al. Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem Commun (Camb) 2006; 3004-6.
85. Pastorin G, Wu W, Wieckowski S, Briand JP, Kostarelos K, Prato M, et al. Double functionalization of carbon nanotubes for multimodal drug delivery. Chem Commun (Camb) 2006; 1182-4.
86. Wu W, Wieckowski S, Pastorin G, Benincasa M, Klumpp C, Briand JP, et al. Targeted delivery of amphotericin B to cells by using functionalized carbon nanotubes. Angew Chem Int Ed Engl 2005; 44:6358-62.
87. Prato M, Kostarelos K, Bianco A. Functionalized carbon nanotubes in drug design and discovery. Acc Chem Res 2008; 41:60-8.
88. Yang H, Liu C, Yang D, Zhang H, Xi Z. Comparative study of cytotoxicity, oxidative stress and genotoxicity induced by four typical nanomaterials: the role of particle size, shape and composition. J Appl Toxicol 2009; 29:69-78.
89. Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G, et al. Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci 2006; 92:5-22.
90. Shvedova AA, Castranova V, Kisin ER, Schwegler-Berry D, Murray AR, Gandelsman VZ, et al. Exposure to carbon nanotube material: assessment of nanotube cytotoxicity using human keratinocyte cells. J Toxicol Environ Health A 2003; 66:1909-26.
91. Akerman ME, Chan WC, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA 2002; 99:12617-21.
92. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug Chem 2004; 15:79-86.
93. Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials 2010; 31:5436-44.
94. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, et al. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 2007; 48:1180-9.
95. Ma J, Fan Q, Wang L, Jia N, Gu Z, Shen H. Synthesis of magnetic and fluorescent bifunctional nanocomposites and their applications in detection of lung cancer cells in humans. Talanta 2010; 81:1162-9.
96. Carpin LB, Bickford LR, Agollah G, Yu TK, Schiff R, Li Y, et al. Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells. Breast Cancer Res Treat 2010; 125:27-34.
97. Kikumori T, Kobayashi T, Sawaki M, Imai T. Anticancer effect of hyperthermia on breast cancer by magnetite nanoparticle-loaded anti-HER2 immunoliposomes. Breast Cancer Res Treat 2009; 113:435-41.
98. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cellpenetrating proteins and peptides. Adv Drug Deliv Rev 2005; 57:637-51.
99. Marschall AL, Frenzel A, Schirrmann T, Schungel M, Dubel S. Targeting antibodies to the cytoplasm. MAbs 2011; 3:3-16.
100. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55:1189-93.
101. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88:223-33.
102. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88:1864-8.
103. Liu X, Wang Y, Nakamura K, Kubo A, Hnatowich DJ. Cell studies of a three-component antisense MORF/ tat/Herceptin nanoparticle designed for improved tumor delivery. Cancer Gene Ther 2008; 15:126-32.
104. Yang H, Wu Q, Tang M, Liu X, Deng H, Kong L, et al. In vitro study of silica nanoparticle-induced cytotoxicity based on real-time cell electronic sensing system. J Nanosci Nanotechnol 10:561-8.
105. Kneuer C, Sameti M, Bakowsky U, Schiestel T, Schirra H, Schmidt H, et al. A nonviral DNA delivery system based on surface modified silica-nanoparticles can efficiently transfect cells in vitro. Bioconjug Chem 2000; 11:926-32.
106. Julien DC, Richardson CC, Beaux MF, 2nd, McIlroy DN, Hill RA. In vitro proliferating cell models to study cytotoxicity of silica nanowires. Nanomedicine: Nanotechnology, Biology and Medicine 2010; 6:84-92.
107. Oberdorster G, Oberdorster E, Oberdorster J. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 2005; 113:823-39.
108. Ye Y, Liu J, Xu J, Sun L, Chen M, Lan M. Nano-SiO2 induces apoptosis via activation of p53 and Bax mediated by oxidative stress in human hepatic cell line. Toxicol In Vitro 24:751-8.
109. Chen TJ, Cheng TH, Chen CY, Hsu SC, Cheng TL, Liu GC, et al. Targeted Herceptin-dextran iron oxide nanoparticles for noninvasive imaging of HER2/ neu receptors using MRI. J Biol Inorg Chem 2009; 14:253-60.
110. Chiu SJ, Ueno NT, Lee RJ. Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin) conjugated polyethylenimine. J Control Release 2004; 97:357-69.
111. Cirstoiu-Hapca A, Bossy-Nobs L, Buchegger F, Gurny R, Delie F. Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles. Int J Pharm 2007; 331:190-6.
112. Choi D, McIlroy D, Nagler J, Aston E, Hrdlicka P, Gustin K, et al. One-dimensional silica structures and their applications to the biological sciences. In: Kumar SSR, Ed. Nanostructured Oxides for Life Sciences: Wiley-VCH 2009; 3:83-108.